Venus Medtech (Hangzhou) (Venus Medtech (Hangzhou)) Debt-to-Equity : 0.28 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Venus Medtech (Hangzhou) Debt-to-Equity?

Venus Medtech (Hangzhou)'s Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $69.28 Mil. Venus Medtech (Hangzhou)'s Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $46.43 Mil. Venus Medtech (Hangzhou)'s Total Stockholders Equity for the quarter that ended in Dec. 2023 was $409.04 Mil. Venus Medtech (Hangzhou)'s debt to equity for the quarter that ended in Dec. 2023 was 0.28.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Venus Medtech (Hangzhou)'s Debt-to-Equity or its related term are showing as below:

VMTHF' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.01 Med: 0.22 Max: 0.5
Current: 0.28

During the past 7 years, the highest Debt-to-Equity Ratio of Venus Medtech (Hangzhou) was 0.50. The lowest was 0.01. And the median was 0.22.

VMTHF's Debt-to-Equity is not ranked
in the Medical Devices & Instruments industry.
Industry Median: 0.215 vs VMTHF: 0.28

Venus Medtech (Hangzhou) Debt-to-Equity Historical Data

The historical data trend for Venus Medtech (Hangzhou)'s Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Venus Medtech (Hangzhou) Debt-to-Equity Chart

Venus Medtech (Hangzhou) Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.05

0.01

0.02

0.25

0.28

Venus Medtech (Hangzhou) Semi-Annual Data
	Dec17	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial							0.02	0.22	0.25	0.26	0.28

Competitive Comparison of Venus Medtech (Hangzhou)'s Debt-to-Equity

For the Medical Devices subindustry, Venus Medtech (Hangzhou)'s Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Venus Medtech (Hangzhou)'s Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Venus Medtech (Hangzhou)'s Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Venus Medtech (Hangzhou)'s Debt-to-Equity falls into.

Venus Medtech (Hangzhou) Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Venus Medtech (Hangzhou)'s Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(69.284	+	46.425)	/	409.043
	=	0.28

Venus Medtech (Hangzhou)'s Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(69.284	+	46.425)	/	409.043
	=	0.28

Venus Medtech (Hangzhou) (OTCPK:VMTHF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Venus Medtech (Hangzhou) Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Venus Medtech (Hangzhou)'s Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Venus Medtech (Hangzhou) (Venus Medtech (Hangzhou)) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Venus Medtech (Hangzhou) Inc (OTCPK:VMTHF) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 88, Jiangling Road, Room 311, 3rd Floor, Block 2, Binjiang District, Hangzhou, CHN, 310051

Website

https://www.venusmedtech.com

Venus Medtech (Hangzhou) Inc is engaged in the development and commercialization of transcatheter solutions for structural heart diseases. It has two TAVR products on the market, namely VenusA-Valve, and VenusA-Plus. VenusA-Valve is its first-generation TAVR device, which is used to treat severe Aortic Stenosis (AS) using a transcatheter approach. VenusA-Plus is an upgraded product of VenusA-Valve. Geographically all of the revenue is derived from Mainland China.

Venus Medtech (Hangzhou) (Venus Medtech (Hangzhou)) Headlines

From GuruFocus

Venus Medtech Acquires Cardiovalve to Optimize its Innovative Products Pipeline of Mitral and Tricuspid Valve Replacement

By PRNewswire PRNewswire • 12-08-2021